BioNTech SE : Strong Q3 figures – Expected cut in 2023 sales guidance
>Q3 results came in above expectations - Already prior to its Q3 reporting, the company announced that it expects Q3 to be hurt by inventory write-offs of its partner Pfizer tied to COMIRNATY. Under the gross profit-sharing agreement with Pfizer, BionTech expected inventory write-offs and other costs booked in Q3 to amount to up to € 0.9bn. Thus, our Q3 estimates reflected write-offs of € 900m. Yesterday, the company announced that actual burdens amounted to only € 50...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.